Terminated PHASE2 INTERVENTIONAL 4-arm NCT03429556

Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty

A Phase 2 Study to Evaluate Safety and Efficacy of EB-001 Intramuscular (IM) Injections in Reducing Musculoskeletal Pain in Subjects Undergoing Elective Abdominoplasty Surgery

Sponsor: Allergan

Conditions Abdominoplasty

Interventions Botulinum Neurotoxin Serotype E Placebo

Updated 7 times since 2018 Last updated: Aug 1, 2019 Started: May 8, 2018 Primary completion: Jul 10, 2018 Completion: Jul 10, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision to terminate early

Other terminated trials from Allergan

See all terminations from Allergan

A PHASE2 clinical study on Abdominoplasty, this trial is terminated or withdrawn. The trial is conducted by Allergan and has accumulated 7 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Sep 2019 — Jan 2021 [monthly]

Terminated PHASE2
Nov 2018 — Sep 2019 [monthly]

Terminated PHASE2

Status: Recruiting → Terminated

▶ Show 2 earlier versions

Jun 2018 — Nov 2018 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Mar 2018 — Jun 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan

Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pasadena, United States